Climb Bio Statistics

Total Valuation

Climb Bio has a market cap or net worth of $748.97 million. The enterprise value is $603.14 million.

Market Cap	748.97M
Enterprise Value	603.14M

Important Dates

The next estimated earnings date is Tuesday, August 11, 2026, before market open.

Earnings Date	Aug 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Climb Bio has 57.26 million shares outstanding. The number of shares has increased by 15.07% in one year.

Current Share Class	57.26M
Shares Outstanding	57.26M
Shares Change (YoY)	+15.07%
Shares Change (QoQ)	+1.24%
Owned by Insiders (%)	0.92%
Owned by Institutions (%)	36.82%
Float	40.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	4.22
P/TBV Ratio	5.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 27.86, with a Debt / Equity ratio of 0.00.

Current Ratio	27.86
Quick Ratio	26.91
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -30.92% and return on invested capital (ROIC) is -21.93%.

Return on Equity (ROE)	-30.92%
Return on Assets (ROA)	-21.27%
Return on Invested Capital (ROIC)	-21.93%
Return on Capital Employed (ROCE)	-40.51%
Weighted Average Cost of Capital (WACC)	4.81%
Revenue Per Employee	n/a
Profits Per Employee	-$1.82M
Employee Count	29
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +906.15% in the last 52 weeks. The beta is 0.10, so Climb Bio's price volatility has been lower than the market average.

Beta (5Y)	0.10
52-Week Price Change	+906.15%
50-Day Moving Average	10.74
200-Day Moving Average	5.76
Relative Strength Index (RSI)	66.31
Average Volume (20 Days)	1,618,515

Short Selling Information

The latest short interest is 3.00 million, so 5.24% of the outstanding shares have been sold short.

Short Interest	3.00M
Short Previous Month	1.91M
Short % of Shares Out	5.24%
Short % of Float	7.46%
Short Ratio (days to cover)	2.64

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-60.08M
Pretax Income	-52.79M
Net Income	-52.79M
EBITDA	n/a
EBIT	-60.08M
Earnings Per Share (EPS)	-$0.79

Full Income Statement

Balance Sheet

The company has $109.56 million in cash and $479,000 in debt, giving a net cash position of $145.83 million or $2.55 per share.

Cash & Cash Equivalents	109.56M
Total Debt	479,000
Net Cash	145.83M
Net Cash Per Share	$2.55
Equity (Book Value)	148.09M
Book Value Per Share	3.10
Working Capital	109.33M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$53.30 million and capital expenditures -$186,000, giving a free cash flow of -$53.49 million.

Operating Cash Flow	-53.30M
Capital Expenditures	-186,000
Depreciation & Amortization	135,000
Net Borrowing	n/a
Free Cash Flow	-53.49M
FCF Per Share	-$0.93

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Climb Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.07%
Shareholder Yield	-15.07%
Earnings Yield	-7.05%
FCF Yield	-7.14%

Analyst Forecast

The average price target for Climb Bio is $20.93, which is 60.02% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$20.93
Price Target Difference	60.02%
Analyst Consensus	Strong Buy
Analyst Count	14
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1